An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess safety and efficacy of long-term use of AL-4943A
(Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic
conjunctivitis.